Showing 5,081 - 5,100 results of 8,903 for search 'significant ((((step decrease) OR (((we decrease) OR (nn decrease))))) OR (mean decrease))', query time: 0.61s Refine Results
  1. 5081

    Table 1_Safety and efficacy comparison of single-stage and two-stage ERCP combined with laparoscopic cholecystectomy: a meta-analysis and systematic review.xlsx by Jian-Xiong Tai (22696688)

    Published 2025
    “…LERV demonstrates superior outcomes compared to the sequential two-step approach of ERCP followed by laparoscopic cholecystectomy (ERCP+LC). …”
  2. 5082

    Table 2_Safety and efficacy comparison of single-stage and two-stage ERCP combined with laparoscopic cholecystectomy: a meta-analysis and systematic review.docx by Jian-Xiong Tai (22696688)

    Published 2025
    “…LERV demonstrates superior outcomes compared to the sequential two-step approach of ERCP followed by laparoscopic cholecystectomy (ERCP+LC). …”
  3. 5083

    The effect of cognitive behavioral therapy-based psychoeducation on substance abuse proclivity in adolescent smokers by Behiye Dilmen Bayar (19133390)

    Published 2025
    “…The difference between the posttest SAPS total mean scores of the control and experimental groups was statistically significant.…”
  4. 5084

    Data for detecting trends in hydroclimatic changes in the Svartberget Krycklan catchment by Tejshree Tiwari (12972713)

    Published 2024
    “…Looking at runoff, we have observed increasing baseflow during the winter but decreasing baseflow during the summers. …”
  5. 5085

    Image 2_Astragaloside IV alleviates GDM via regulating gut microbiota and gut microbiota metabolomic.tif by Fengge Wang (4347442)

    Published 2025
    “…</p>Results<p>After the 25-day intervention, the GDM model + AS IV group showed significantly decreased fasting blood glucose levels (p = 0.0003), mean insulin levels (p = 0.0001), and insulin resistance index (p = 0.0001). …”
  6. 5086

    Image 1_Astragaloside IV alleviates GDM via regulating gut microbiota and gut microbiota metabolomic.tif by Fengge Wang (4347442)

    Published 2025
    “…</p>Results<p>After the 25-day intervention, the GDM model + AS IV group showed significantly decreased fasting blood glucose levels (p = 0.0003), mean insulin levels (p = 0.0001), and insulin resistance index (p = 0.0001). …”
  7. 5087

    Table 1_Astragaloside IV alleviates GDM via regulating gut microbiota and gut microbiota metabolomic.xlsx by Fengge Wang (4347442)

    Published 2025
    “…</p>Results<p>After the 25-day intervention, the GDM model + AS IV group showed significantly decreased fasting blood glucose levels (p = 0.0003), mean insulin levels (p = 0.0001), and insulin resistance index (p = 0.0001). …”
  8. 5088

    Table 2_Astragaloside IV alleviates GDM via regulating gut microbiota and gut microbiota metabolomic.xlsx by Fengge Wang (4347442)

    Published 2025
    “…</p>Results<p>After the 25-day intervention, the GDM model + AS IV group showed significantly decreased fasting blood glucose levels (p = 0.0003), mean insulin levels (p = 0.0001), and insulin resistance index (p = 0.0001). …”
  9. 5089

    Data_Sheet_1_Investigating the impact of mental rehearsal on prefrontal and motor cortical haemodynamic responses in surgeons using optical neuroimaging.docx by Hemel N. Modi (19919895)

    Published 2024
    “…Mean objective performance score was significantly higher following MR compared with TR (p = 0.043).…”
  10. 5090

    Data Sheet 1_Real world evidence of dupilumab effectiveness in a Colombian cohort of patients diagnosed with severe asthma.docx by Abraham Alí-Munive (21347201)

    Published 2025
    “…FEV1 measurements after one or two years of dupilumab treatment were significantly lower than baseline (p = 0.03). Mean change from baseline in FEV<sub>1</sub> was 302.1 ± 481.97 ml (n = 19), 282.00 ± 231.99 ml (n = 10), and 248.18 ± 281.21 ml (n = 11) in the 2–4-, 11–13-, and 19–25-month follow-up periods, respectively. …”
  11. 5091

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
  12. 5092

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
  13. 5093

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
  14. 5094

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
  15. 5095

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
  16. 5096

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
  17. 5097

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
  18. 5098

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
  19. 5099

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
  20. 5100

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”